Showing results (1-10 of 45) with videos related to
Sort By:
Pageof 5
Urology|September 17, 2002
Novel trial designs: which agents and how do we test them?William Kevin KellyUrology|January 30, 2004
Use of nomograms for predicting survival in patients with castrate prostate cancerMatt Galsky, William Kevin KellyExpert Review of Endocrinology & Metabolism|March 6, 2012
Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancerKaren E Knudsen, William Kevin KellyNature Clinical Practice. Oncology|November 3, 2005
Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acidWilliam Kevin Kelly, Paul A MarksThe Canadian Journal of Urology|August 23, 2011
New treatment options for castrate-resistant prostate cancer: a urology perspectiveLeonard G Gomella, Francisco Gelpi, William Kevin KellyThe Pharmacogenomics Journal|July 11, 2024
Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertensionJulia C F Quintanilha, William Kevin Kelly, Federico InnocentiOncology (Williston Park, N.Y.)|February 19, 2016
The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3Praveen Ramakrishnan Geethakumari, Michael S Cookson, William Kevin Kelly, et al.Advances in Cancer Research|August 26, 2004
Histone deacetylase inhibitorsPaul A Marks, Victoria M Richon, Thomas Miller, et al.BMC Urology|July 30, 2013
Dysregulated methylation at imprinted genes in prostate tumor tissue detected by methylation microarrayDaniel I Jacobs, Yingying Mao, Alan Fu, et al.Plos One|August 29, 2022
A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancerYash B Shah, Amy L Shaver, William Kevin Kelly, et al.Pageof 5